“Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder, characterised by difficulties with communication, social interaction, repetitive behaviours, restricted interests, and varying levels of intellectual disability. Aetiology remains unclear for many patients and the underlying physiology is complex. Approved pharmacological treatments of ASD target irritability, temper tantrums, and agitation, with no therapies targeting core ASD symptoms.

This double-blind, randomised, placebo-controlled Phase II/III clinical trial investigated the efficacy and safety of NTI164, a novel full-spectrum medicinal cannabis product with <0.3% tetrahydrocannabinol (THC), in paediatric patients with Level II/III ASD.

Participants were recruited from a tertiary paediatric neurology clinic and randomised to receive NTI164 up to 20 mg/kg/day or placebo for an 8-week double-blind phase; participants receiving placebo were able to receive NTI164 in an 8-week open label phase following the double-blind phase. Safety assessments, clinician-, and caregiver-rated tools measuring symptoms were utilised at baseline and Week 8. Analysis of Covariance (ANCOVA) was used for statistical analyses.

NTI164 demonstrated an excellent safety profile, and statistically significant and meaningful improvements compared to placebo in overall clinical severity, adaptive functioning, social responsiveness, and affective symptoms. Caregivers also reported improved family experiences and quality of life with NTI164. Participants who transitioned from placebo to NTI164 open label reported similar improvements as those reported during the double-blind phase.

NTI164 significantly improved core and associated symptoms of ASD compared to placebo.

Consistent benefits reported by both clinicians and caregivers in both open label and double-blind contexts supports further clinical development of NTI164 in ASD.”

https://pubmed.ncbi.nlm.nih.gov/42561512

“The multi-domain improvements observed with NTI164 treatment compared to placebo reported in this study support utility as a broader therapeutic intervention which can address ASD symptoms.

This randomised, double-blind, placebo-controlled clinical trial in children and adolescents with moderate-severe ASD showed NTI164 meaningfully improves global impression of clinical severity, adaptive functioning, aspects of social responsiveness, mood, anxiety, and family experiences, with an excellent safety profile.”

https://www.neurotherapeuticsjournal.org/article/S1878-7479(26)00203-5/fulltext